We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Physical,Histological,and Genetic Analyses of Lipid-rich Atherosclerotic Plaques

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00449306
Recruitment Status : Active, not recruiting
First Posted : March 20, 2007
Last Update Posted : October 25, 2016
Information provided by (Responsible Party):

March 19, 2007
March 20, 2007
October 25, 2016
March 2001
July 2017   (Final data collection date for primary outcome measure)
To uncover mechanisms of cardiovascular diseases [ Time Frame: 3 years ]
Not Provided
Complete list of historical versions of study NCT00449306 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Physical,Histological,and Genetic Analyses of Lipid-rich Atherosclerotic Plaques
Physical,Histological,and Genetic Analyses of Lipid-rich Atherosclerotic Plaques

Lipid-rich atherosclerotic plaques, or "vulnerable plaques" are prone to rupture, causing local intravascular thrombosis, with subsequent grave clinical consequences. Atherosclerotic plaques normally removed during surgery, and peripheral blood samples will be studied to achieve the following objectives:

"1" Define histological features of the vulnerable plaque, analyze its physical characteristics, and investigate selected gene expression.

"2" Study biomarkers of inflammation in conjunction with the presence of vulnerable plaques.

"3" Explore the potential role of infection in atherogenesis.

Not Provided
Observational Model: Case Control
Time Perspective: Cross-Sectional
Not Provided
Retention:   Samples Without DNA
Tissue for RNA extraction (frozen); Tissue for histological analysis (formalin fixation); Plasma for CV biomarkers (frozen)
Probability Sample
Primary Care Clinic patients
  • Atherosclerosis
  • Aortic Aneurysm
  • Peripheral Vascular Diseases
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Active, not recruiting
July 2018
July 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Evidence of symptomatic carotid stenosis exceeding 60%(TIAs or stroke within the last 6 months), and asymptomatic carotid artery stenosis (presenting with progressive carotid stenosis, exceeding 70%)
  • Abdominal aortic aneurysm, and aortic occlusive disease
  • Peripheral occlusive or aneurysmal disease

Exclusion Criteria:

  • Non-compliant patients, incapable of granting approval by informed consent
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Sheba Medical Center
Sheba Medical Center
  • University Hospital Goettingen
  • Carmel Medical Center
  • CVpath Institute, Inc.
Principal Investigator: Jacob Schneiderman, MD Department of Vascular Surgery, Sheba Medical Center, Tel Hashomer
Sheba Medical Center
October 2016